36341-25-0
36341-25-0 結(jié)構(gòu)式
基本信息
2-(4-羥基-3-甲氧基苯基)苯并噻唑
4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚
Y-109
YL-109
Y-109
Y109
Phenol, 4-(2-benzothiazolyl)-2-methoxy-
4-(benzo[d]thiazol-2-yl)-2-Methoxyphenol
4-(1,3-Benzothiazol-2-yl)-2-methoxyphenol
2-(4-HYDROXY-3-METHOXYPHENYL)BENZOTHIAZOLE
4-(3H-1,3-benzothiazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one
物理化學(xué)性質(zhì)
制備方法
121-33-5
137-07-5
36341-25-0
以香蘭素和2-氨基苯硫酚為原料合成2-(4-羥基-3-甲氧基苯基)苯并噻唑的一般步驟：在催化反應(yīng)中，將香蘭素（3mmol）、2-氨基苯硫酚（3mmol）和CdS納米球（5mg）的混合物置于100mL雙壁石英燒瓶中，該燒瓶配備有水入口和出口以維持反應(yīng)溫度在室溫。反應(yīng)在甲醇（20mL）中進(jìn)行，并在攪拌條件下將反應(yīng)混合物暴露于可見(jiàn)光下照射指定時(shí)間（參見(jiàn)表3）。反應(yīng)進(jìn)程通過(guò)薄層色譜（TLC）和氣相色譜（GC）監(jiān)測(cè)。反應(yīng)完成后，通過(guò)旋轉(zhuǎn)蒸發(fā)去除甲醇，將殘余物溶解于二氯甲烷中。通過(guò)離心分離催化劑與反應(yīng)混合物。隨后，蒸發(fā)二氯甲烷至干，產(chǎn)物通過(guò)硅膠G60柱色譜法進(jìn)行純化。
參考文獻(xiàn)：
[1] Chemistry Letters, 2004, vol. 33, # 3, p. 274 - 275
[2] Tetrahedron Letters, 2013, vol. 54, # 9, p. 1090 - 1096
[3] Heterocycles, 2007, vol. 71, # 8, p. 1837 - 1842
[4] Research on Chemical Intermediates, 2015, vol. 41, # 10, p. 7509 - 7516
[5] Journal of Heterocyclic Chemistry, 2009, vol. 46, # 1, p. 91 - 95
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 5mg | 550元 |
| 2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 10mM * 1mLin DMSO | 600元 |
| 2025/05/22 | HY-18619 | 4-(苯并[D]噻唑-2-基)-2-甲氧基苯酚 YL-109 | 36341-25-0 | 10mg | 900元 |
常見(jiàn)問(wèn)題列表
YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.
YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells.
Cell Proliferation Assay
| Cell Line: | MCF-7 and MDA-MB-231 cells |
| Concentration: | 0.001, 0.01, 0.1, 1, 10 μM |
| Incubation Time: | 96 hours |
| Result: | Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC 50 =85.8 nM and 4.02 μM, respectively). |
YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo.
| Animal Model: | BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells |
| Dosage: | 15 mg/kg |
| Administration: | S.c. every 2 days for 63 days |
| Result: | Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells. |